Gut bacteria and their activity in autism: from causes to treatment

Studies have shown that 48.67% of individuals with ASD have gastrointestinal symptoms (Wang et al., 2022), and the incidence of gastrointestinal symptoms in children with ASD is four times higher than that in the general population. Common symptoms include constipation, diarrhea, bloating, abdominal pain, reflux, vomiting, flatulence, foul-smelling stools, and food allergies (Fulceri et al., 2016; Santocchi et al., 2016; Iovene et al., 2017; Marler et al., 2017). An increasing body of evidence suggests that gut microbiota dysbiosis in ASD patients is closely associated with gastrointestinal symptoms, and the severity of these symptoms is strongly correlated with the clinical manifestations of ASD (Kreider et al., 2021). Specifically, there is a clear connection between the gut microbiota of ASD patients and their neurobehavioral symptoms. Studies by Deng, W (Deng et al., 2022)and Liu, J (Liu et al., 2022)have found that gastrointestinal symptoms, such as diarrhea and constipation, may exacerbate behavioral issues in children with ASD, such as rigidity, hyperactivity, and social withdrawal. Animal studies by Sharon G (Sharon et al., 2019)and others have shown that when the gut microbiota from ASD patients is transplanted into GF mice, the mice exhibit symptoms similar to those of ASD, further supporting the link between gut microbiota and the pathogenesis of ASD. Research also indicates that ASD patients exhibit abnormalities in gut microbiota in terms of biomass, biodiversity, richness (Ma et al., 2019; Chang et al., 2024), and structure (Chang et al., 2024). To better understand this phenomenon, we have summarized six relevant studies from five countries over the past three years (see Table 1). As shown in Table 1, the gut microbiota of ASD patients differs significantly from that of the general population, and these patients' gut microbiota undergoes noticeable changes. Although these studies have not consistently identified specific microbial species that change, this may be due to differences in factors such as diet, age, sex, population, and the severity of autism (Pulikkan et al., 2018). Nonetheless, the studies consistently suggest that ASD patients often exhibit microbial imbalances of various types. The most evident change is the decreased ratio of Bacteroidetes/Firmicutes, which may reflect the reduced relative abundance of Bacteroidetes (Alharthi et al., 2022), though this shift could also be influenced by confounding factors such as medication use.

Human gut microbiota colonization begins during the fetal period and matures to a composition close to that of adults by around 3 years of age—a critical window that overlaps with the golden period of childhood brain development (Collado et al., 2016; Margolis et al., 2021). Emerging evidence indicates that gut microbiota can exert significant influences on brain function (Damiani et al., 2023). Dysbiosis of gut microbiota is closely linked to the onset and progression of ASD, exerting impacts on both gastrointestinal symptoms and neurobehavioral manifestations through microbiota-gut-brain axis-related mechanisms. Specifically, gut microbiota dysbiosis alters microbial metabolites and disrupts the intestinal microenvironment, establishing bidirectional communication between the gut and the brain through integrated effects on the nervous, immune, and endocrine systems, ultimately modulating brain function (Chernikova et al., 2021; Socala et al., 2021) (Figure 1).

In animal experiments, Sharon G et al. transplanted gut microbiota from ASD patients or typically developing (TD) controls into GF mice, demonstrating that colonization with ASD-derived microbiota was sufficient to induce hallmark autistic-like behaviors (Sharon et al., 2019). They detected reduced levels of specific metabolite profiles—particularly 5-aminovaleric acid (5AV) and taurine—in the ASD group, proposing that gut microbiota regulate murine behavior by producing neuroactive metabolites (Sharon et al., 2019). Moreover, ASD-associated microbiota promote widespread alternative splicing of ASD-related genes in the brain (Stilling et al., 2018), and the gut microbiome can alter splicing programs at the level of ribosomal binding proteins (RBPs) (Sharon et al., 2019).

De Angelis and colleagues noted that gut microbiota dysbiosis is commonly associated with impairment of the intestinal mucosal barrier, which increases intestinal permeability to neurotoxic compounds derived from diet or gut bacterial metabolism. This disruption leads to dysregulation of neuromodulatory mechanisms and impairment of normal brain development (De Angelis et al., 2015). Additionally, accumulating research confirms that alterations in gut microbial composition are linked to immune dysfunction in ASD patients. Gut microbiota can indirectly influence the innate immune system, thereby altering circulating levels of pro-inflammatory and anti-inflammatory cytokines and impacting microglial homeostasis (Erny et al., 2015; Alharthi et al., 2022).

In summary, a balanced gut microbial composition is essential for maintaining microbial homeostasis, whereas perturbations in microbial composition can exert adverse effects on human health, contributing to the pathogenesis and progression of ASD.

Amino acids serve as precursors for various potent neuroactive molecules (such as classical neurotransmitters), with their metabolites including tryptophan, 5-hydroxytryptamine (5-HT), Gamma-Aminobutyric Acid (GABA), glutamate, and dopamine (DA). 5-HT supports the development of the enteric nervous system (ENS) by activating intestinal peristalsis and electrolyte secretion (Heredia et al., 2013; Mawe and Hoffman, 2013). Studies have revealed insufficient intestinal 5-HT production and reduced bioavailability in ASD patients (Golubeva et al., 2017), accompanied by evidence of abnormal 5-HT metabolism (Lim et al., 2016; Muller et al., 2016). Furthermore, 5-HT metabolites can alter intestinal vagal afferent activity, potentially directly impacting vagal nerve signaling to the brain (Slattery et al., 2006).

Alterations in the levels of several amino acids and their derived metabolites in the feces and/or plasma of ASD patients are closely associated with ASD severity (Al-Otaish et al., 2018; Needham et al., 2021). In their research, Sharon, G et al. compared colonic contents and serum samples between ASD mice and TD mice, identifying 27 significantly differential metabolites among 313 detected compounds in ASD mice's colonic contents, with generally elevated amino acid concentrations (Sharon et al., 2019). A study by Chang, X et al. further revealed associations between amino acid biosynthesis and neurodegeneration (Chang et al., 2024). Research by Zheng, Y, Kang, D.W, and Chamtouri, M et al. has indicated that altered levels of fecal ammonium salts and various amino acid metabolites (such as p-cresol and 4EP)) are associated with ASD (Kang et al., 2018; Zheng et al., 2021; Chamtouri et al., 2023b).

Observational studies by Mariem Chamtouri et al. found significantly increased total amino acid content and levels of 14 specific amino acids in the feces of ASD children, with a higher glutamate ratio compared to healthy children, which may be related to imbalanced intestinal transamination reactions associated with ASD (Chamtouri et al., 2023b). Studies by Lu Xiao et al (Xiao et al., 2021). confirmed the presence of tryptophan metabolism disorders in ASD patients, characterized by decreased plasma tryptophan levels and an elevated kynurenine/tryptophan ratio. Kynurenine and kynurenic acid can induce increased interleukin-6 (IL-6) levels (Savitz et al., 2015), and related studies have confirmed that IL-6 is one of the most significantly elevated cytokines in ASD patients (Saghazadeh et al., 2019; Filippova et al., 2022; Williams et al., 2022). Under physiological conditions, kynurenic acid exhibits neuroprotective effects, but abnormal elevation of this substance may produce neurotoxicity (Erhardt et al., 2017). Therefore, kynurenic acid, kynurenine, and IL-6 hold promise as potential biomarkers for ASD diagnosis.

P-cresol and 4EP, primarily derived from the metabolism of dietary tyrosine by gut microbiota (Persico and Napolioni, 2013), exhibit abnormal levels in ASD patients that are closely associated with clinical symptoms. P-cresol and its metabolite p-cresyl sulfate are known uremic toxins that can exert negative effects on multiple brain functions (Pascucci et al., 2020). Gevi, F et al. detected significantly elevated levels of p-cresol and p-cresyl sulfate in blood, urine, and fecal samples from ASD patients (Gevi et al., 2020), and proposed that increased levels of these substances are associated with exacerbation of repetitive stereotyped behaviors, communication impairments, and cognitive deficits. Animal experiments by Tiziana Pascucci et al. further confirmed that p-cresol can acutely induce autistic-like behaviors and cause abnormal DA metabolism in reward circuits (Pascucci et al., 2020). Notably, elevated urinary p-cresol levels in autistic children are associated with chronic constipation, suggesting that prolonged intestinal transit time may be one of the main factors contributing to increased intestinal absorption of potential neuroactive compounds such as p-cresol (Gabriele et al., 2016).

High concentrations of 4EP and its metabolite 4-ethylphenyl sulfate (4EPS) in human urine, plasma, or feces are closely linked to autism-related neural and behavioral changes (Stewart et al., 2022; Day et al., 2023). Needham, B.D et al. found through experiments with bioengineered gut bacteria that mice exposed to 4EPS exhibit anxiety-like behaviors, potentially through effects on oligodendrocyte function and myelin patterns in the brain (Needham et al., 2022). Studies by Hsiao, E.Y et al. also confirmed a potential association between elevated levels of 4EPS in plasma and urine of ASD patients and anxious and irritable behaviors (Hsiao et al., 2013). Accumulation of 4EPS in the brain can disrupt functional connectivity between regions such as the hippocampus, thalamus, amygdala, hypothalamus, and cortex (Needham et al., 2022), which are all involved in regulating anxiety behaviors and responses to stress stimuli (Goode et al., 2019; Fischer, 2021).

Bile acids are a group of hydroxylated steroid acids that serve as the main component of bile. They not only facilitate the digestion of dietary lipids and regulate lipid metabolism but also play a crucial role in maintaining epithelial barrier function in the small intestine (Inagaki et al., 2006; Gadaleta et al., 2011). A dynamic bidirectional regulatory relationship exists between the intestinal microbial community and bile acids: the microbiota can precisely regulate the metabolism and synthesis of bile acids, while the composition and size of the bile acid pool in turn influence the diversity and homeostasis of the intestinal microbiota (Guo X. et al., 2022).

Studies have shown that there are defects in the bacterial transformation of bile acids in the intestines of ASD patients. Animal experiments by Golubeva, A V et al. revealed that ASD model mice exhibit significantly reduced plasma bile acid levels and deficient ileal bile acid signaling; simultaneously, the content of all conjugated bile acids in the feces of model mice was significantly increased, while the secondary bile acid pool was markedly reduced, indicating severe bile acid loss (Golubeva et al., 2017). It is known that bile acids can activate colonic peristalsis by stimulating the release of intestinal serotonin and calcitonin gene-related peptide calcitoningene-related peptide(CGRP) (Alemi et al., 2013). Therefore, reduced levels of secondary bile acids lead to delayed colonic transit, which further exacerbates gastrointestinal symptoms such as constipation in ASD patients. In addition, slowed intestinal transit time is one of the important reasons for increased intestinal absorption of more potential neuroactive compounds in ASD patients (Gabriele et al., 2016), a process that may be closely related to impaired intestinal barrier function.

Short-chain fatty acids (SCFAs) are metabolites produced by gut bacteria through the fermentation of dietary fiber. As the most abundant bacterial metabolites in the human colon, approximately 95% of SCFAs can be absorbed by the intestine and utilized by the human body, mainly including acetate, propionate, and butyrate (Chen et al., 2017). Evidences have shown that SCFAs exert effects on the brain through two pathways: activating G Protein-Coupled Receptor 41(GPR41) (i.e., free fatty acid receptor 3, which is highly expressed in the brain and blood-brain barrier), and inhibiting histone deacetylase (HDAC) in a dose-dependent manner (Falomir-Lockhart et al., 2019; Guo C. et al., 2022).

SCFAs play multiple regulatory roles in the gut microbiota-gut-brain axis. They can influence the function of the intestinal immune system by regulating gene expression (Iglesias-Vazquez et al., 2020), and can also be absorbed by the central nervous system (CNS) to participate in maintaining the integrity of the blood-brain barrier (BBB), supporting brain development, regulating homeostasis, and modulating neuroinflammation (Silva et al., 2020; Wenzel et al., 2020; Settanni et al., 2021). Clinical studies have found that the content of certain SCFAs in the feces of children with ASD is higher than that in healthy children (Wang et al., 2012; Lagod and Naser, 2023). Research by Xiao, L et al. confirmed that abnormal metabolism of specific SCFAs affects the permeability of the BBB in ASD patients, thereby exerting adverse effects on the neurodevelopment and/or function of their central nervous system (Xiao et al., 2021); in addition, such metabolic abnormalities may lead to changes in mitochondrial function and interfere with the epigenetic regulation of ASD-related genes (Settanni et al., 2021).

Propionic acid (PPA), a short-chain fatty acid produced by anaerobic gut bacteria such as Clostridium and Propionibacterium, has been shown to induce various behavioral, immune, and mitochondrial effects in rodent models highly similar to human autism spectrum disorders (Macfabe, 2012). The concentration of PPA in the feces of ASD children is significantly increased (Coretti et al., 2018), and excessive PPA may have negative impacts on health and behavior through multiple mechanisms, becoming a potential inducer of ASD pathogenesis (Al-Owain et al., 2013). Studies have further confirmed that high concentrations of PPA can cross the BBB and directly damage neurons (Choi et al., 2018), and are closely associated with neurological diseases such as autism (Al-Lahham et al., 2010). Animal experiments have also shown that intracerebroventricular injection of PPA can induce ASD-like behaviors, and its underlying mechanism may be related to abnormal neurotransmitter regulation (Mitsui et al., 2005; MacFabe et al., 2007; Macfabe, 2012). Therefore, reducing PPA exposure and regulating the balance of intestinal microbiota may help reduce the risk of ASD or improve related symptoms.

Butyrate can promote neuroplasticity and memory formation (Stilling et al., 2016), influence social behavior by regulating GABA signaling, and enhance social ability in autistic mouse models. Studies have shown that long-term butyrate treatment can improve ASD-related symptoms (Kratsman et al., 2016). However, the content of butyrate in the feces of ASD children is generally lower than that in healthy children (Zhang et al., 2018; Liu et al., 2019), which may exacerbate social behavior deficits in ASD children by affecting the balance of excitatory/inhibitory systems (Kratsman et al., 2016). Nevertheless, increased butyrate concentrations in fecal samples of ASD patients have also been observed in different studies (Wang et al., 2012; Coretti et al., 2018). Animal experiments indicate that the effects of butyrate on brain development and function are dose-dependent, and high-dose butyrate may induce stress-like responses (Gagliano et al., 2014). In addition, as an anti-inflammatory short-chain fatty acid, butyrate protects colonic health and has been proven to protect ASD cells under oxidative stress and enhance mitochondrial function under physiological stress; meanwhile, butyrate can regulate the synthesis of neurotransmitters such as DA, norepinephrine, and epinephrine, as well as the expression of neurotransmitter genes and ASD-related genes in cell line models (Nankova et al., 2014).The heterogeneity observed in these findings may stem from methodological variations (e.g., fecal vs. plasma detection), cohort characteristics (e.g., age/dietary habits/clinical phenotypes), biological context dependencies (e.g., dose-effect relationships), and sample collection and processing protocols. For instance, discrepancies in the timing, site, and handling of samples across studies can significantly influence results, as gut microbial metabolic activities may fluctuate throughout the day. Additionally, factors such as storage temperature and duration during sample processing can affect the stability of gut microbiota metabolites, thereby introducing deviations in detection outcomes. Notably, in ASD subgroups with constipation, prolonged colonic transit time may lead to localized elevation of butyrate concentrations while reducing systemic absorption. When constipation coexists with other symptoms such as food allergies, further disruption to microbial metabolism may occur. This compartmentalized distribution of metabolites could partially explain contradictory results across different studies (Table 2).

The hypothalamic-pituitary-adrenal (HPA) axis is a stress-responsive system in the human body (Table 3). When activated, neurotransmitters such as corticotropin-releasing hormone are released in the brain, exerting effects on brain function (Borodovitsyna et al., 2018). Chronic stress can lead to abnormalities in brain structure and functional connectivity, impairing language cognition, sensory perception, and other brain functions, thereby contributing to mental disorders (Dinan and Cryan, 2017). Sudo and colleagues found that the absence of gut microbiota affects the HPA axis, altering endocrine responses to stress (Sudo et al., 2004). Further studies have confirmed that gut microbiota may influence social behaviors in ASD children by participating in discrete neuronal circuits involved in brain stress responses (Wu et al., 2021). Cortisol, the primary HPA axis hormone secreted by the adrenal cortex, affects metabolism, cognition, and behavior (Gao et al., 2022); it also mediates synaptic pruning by activating microglia, thereby influencing the excitatory/inhibitory imbalance in the central nervous system (Gao et al., 2022). Clinical evidence shows significant abnormalities in HPA axis-related hormones in ASD (Singh et al., 2017; Ames et al., 2020; Worsham et al., 2021). Alterations and imbalances in the HPA axis of ASD patients result in significantly elevated cortisol levels in peripheral blood (Spratt et al., 2012). Thus, peripheral cortisol may be partially responsible for the development of ASD (Cornell et al., 2022). Additionally, scholars have proposed an association between maternal premenstrual syndrome and/or postnatal environmental stress factors and the risk of ASD in offspring (Manzari et al., 2019), and maternal cortisol levels are correlated with the developmental trajectory of cognitive function in full-term infants at one year of age (Davis and Sandman, 2010).

The vagus nerve serves as a critical link between gut microbiota and the brain, communicating with the brain through multiple synaptic connections in the nucleus tractus solitarius of the brainstem (Table 3). The ENS, richly distributed in the intestinal wall, forms an independent peripheral nervous system that can transmit information related to digestion, absorption, and immunity upward to the thalamus of the central nervous system. The brain can influence the community structure and function of gut microbiota through the autonomic nervous system by regulating local intestinal motility, transportation, secretion, intestinal permeability, and potentially through luminal secretion of hormones that directly regulate microbial gene expression (Martin et al., 2018). Growing evidence confirms that the vagus nerve system plays a key role in regulating the gut-brain axis (Vuong and Hsiao, 2017; Yu et al., 2020); dysregulation of the vagus nerve system can lead to ASD (Vuong and Hsiao, 2017; Sgritta et al., 2019), while the vagus nerve and ENS can also be directly influenced by neurotransmitter molecules produced by the microbiota (Silva et al., 2020). Abnormalities in 5-HT and kynurenine metabolites in ASD patients affect the activity of intestinal vagal afferents, potentially directly impairing vagal nerve signaling to the brain (Slattery et al., 2006). Golubeva, A V et al (Golubeva et al., 2017)found in animal experiments that ASD model mice (BTBR strain) exhibit significantly delayed overall intestinal transit, accompanied by colonic elongation and reduced fecal water content. Kim, J W et al (Kim et al., 2013). also reported impaired small intestinal peristalsis in an ASD rat model in animal experiments. Healthy gastrointestinal peristalsis largely depends on ENS, and delayed colonic transit in ASD model mice may be related to abnormal development of ENS motor circuits (Golubeva et al., 2017).

There is a link between ASD and systemic immune dysfunction (excessive inflammation) (Table 3) (Zhang et al., 2023). Studies have shown prominent central and peripheral inflammatory responses in ASD patients, with not only systemic immune dysregulation but also abnormal neuroimmune function (Onore et al., 2012). ASD patients often exhibit a state of chronic neuroinflammation, characterized by elevated levels of pro-inflammatory cytokines and chemokines (e.g., TNF-α, IL-6, Interleukin-8(IL-8)) in cerebrospinal fluid (CSF) and activation of microglia in the brain tissue of ASD patients (Vargas et al., 2005; Li et al., 2009; Onore et al., 2012; Zheng et al., 2021). Studies have also confirmed that upregulated expression of IL-6 and Interleukin-17(IL-17) in ASD individuals or animal models induces autistic-like behaviors in the models (Kim et al., 2017; Azhari et al., 2019), and blocking these cytokines with neutralizing antibodies can alleviate autistic behaviors (Choi et al., 2016; Azhari et al., 2019). Microglia, which play a role in innate immune function (Boche et al., 2013), are crucial for neuronal development; they participate in synaptogenesis and are responsible for pruning excess synaptic connections during childhood, a process essential for the development of functional neural circuits (Paolicelli et al., 2011). Elevated levels of pro-inflammatory cytokines and chemokines, along with abnormal activation of microglia in ASD patients, disrupt synaptic maintenance and lead to dysregulation of synaptic pruning, thereby contributing to the occurrence and progression of ASD (Koyama and Ikegaya, 2015). Inflammatory processes are involved in the pathogenesis of ASD; immune activation induces the kynurenine pathway (KP), i.e., the tryptophan catabolic pathway (Yildirim et al., 2023). There is a close interaction between the cytokine IL-6 and KP (Butler et al., 2022; Francis et al., 2022). Yildirim, V et al. confirmed elevated levels of IL-6 and kynurenic acid in ASD patients, suggesting abnormal immune responses in the brains of ASD patients that may lead to abnormal neurotransmission (Yildirim et al., 2023). SHANK3 is a synaptic scaffold protein, and mutations in SHANK3 are associated with ASD. Zhang, L et al (Zhang et al., 2023). demonstrated that vagal SHANK3 can limit excessive inflammation induced by lipopolysaccharide (LPS) in experimental animals, providing new molecular insights into inflammatory dysregulation in some ASD individuals.

The intestinal barrier and BBB are two natural barriers within the gut-brain axis (Table 3). Gut microbiota and their related metabolites are involved in regulating the functions of these two barriers (Martin et al., 2018); they can alter the expression of intestinal tight junction proteins (Braniste et al., 2014), influence the growth and development of neuroglial cells, and regulate neuronal activity by modulating the neuro-glial microenvironment. Gut bacteria and their metabolites can regulate intestinal barrier function (Kelly et al., 2015), while the colon of ASD patients may have poor resilience to metabolic stressors such as intestinal inflammation or hypoxia (Golubeva et al., 2017). Thus, under stress or physicochemical insults, the permeability of the BBB may increase, or even intestinal mucosal barrier damage may occur, followed by the release of inflammatory factors. These inflammatory factors can ascend to invade the brain, causing brain function impairment, and invade the gastrointestinal system, leading to gastrointestinal symptoms. Dysbiosis of gut microbiota in ASD patients is also commonly associated with intestinal mucosal barrier damage; such dysbiosis increases intestinal permeability to neurotoxic compounds, resulting in dysregulation of neuromodulatory mechanisms and impairment of normal brain development (De Angelis et al., 2015).

ASD is associated with significantly reduced BBB integrity (Obrenovich, 2018), leading to increased permeability (Fiorentino et al., 2016). The microbiota is involved in regulating BBB integrity. Alterations in levels of gut microbiota-derived metabolites such as p-cresol and its metabolite p-cresyl sulfate in ASD patients affect brain function; these metabolites, known as uremic toxins (Pascucci et al., 2020), can influence BBB permeability, impairing its integrity. Impaired BBB integrity may facilitate the entry of microbiota-derived metabolites into the central nervous system, contributing to the pathogenesis of ASD. Furthermore, systemic immune activation commonly observed in ASD patients may cause destructive changes in the blood-brain barrier (Martin et al., 2018) (Table 3).

In recent years, attention has been paid to the impact of exercise on the microbiota. Exercise can balance the relationship between beneficial and pathogenic bacteria in the gut (Xue et al., 2023), and exercise intervention can improve motor skills and behavioral outcomes in autistic children (Yu et al., 2018), including stereotyped behaviors, social-emotional functions, cognition, and attention (Bremer et al., 2016; Toscano et al., 2018). Toscano, CVA et al. conducted a 48-week exercise intervention in ASD patients and found that exercise therapy had beneficial effects on metabolic indicators and quality of life in ASD patients (Toscano et al., 2018). Liang, X et al. concluded in their research analysis that chronic exercise intervention has a small to moderate significant impact on overall executive functions (EFs), inhibitory control, and cognitive flexibility in children and adolescents with ASD. Cognitively engaging exercises (e.g., martial arts and movement games) have beneficial effects on overall EFs in children and adolescents with ASD. This may be because exercise promotes co-activation between the cerebellum and dorsolateral prefrontal cortex in ASD patients, thereby improving their cognitive function (Liang et al., 2022). Cytokines released after exercise can play an important role in regulating neuronal metabolism (Gabriele et al., 2014). Although exercise therapy can improve symptoms in ASD patients (Schmitz et al., 2017), there are still few studies on how exercise therapy exerts therapeutic effects by improving the gut microbiota of ASD patients.

Food preferences and dietary patterns are considered key factors influencing the development of autism spectrum disorder. Moreover, maternal diet is also related to the development of ASD in offspring (Sullivan et al., 2014). Adequate intake of folic acid and vitamins during pregnancy can reduce the risk of ASD (Suren et al., 2013), while a high-fat diet during pregnancy increases the risk of ASD (Peretti et al., 2019). Therefore, dietary intervention is often used as one of the means to treat ASD. Many specialized diets are considered beneficial for ASD. For example, a gluten-free diet (GFD) is thought to improve ASD-related behavioral and intellectual problems (Croall et al., 2021), and a gluten-free casein-free diet (GFCF) is also believed to have a positive impact on the health status of ASD patients (Whiteley et al., 2010). A high-fat (65-90%) ketogenic diet (KD) is often used to treat ASD, and omega-3 fatty acids (ω-3), commonly used as food supplements, are also regarded as effective complementary and alternative therapeutic agents for ASD (Bent et al., 2009). ASD can lead to increased inflammatory cytokines, oxidative stress, and neurotransmitter dysfunction, so autistic children often have omega-3 long-chain polyunsaturated fatty acid (PUFA) metabolic defects (Das, 2013). Supplementation with ω-3 is beneficial to brain and visual development, function, as well as behavior and emotional regulation (Kidd, 2007). Fecal amino acids can also be used to design personalized diets to prevent or minimize ASD-related cognitive impairments. The amino acid profile from protein sources can be applied in the early stages of autism development to prevent or minimize cognitive impairments and neurodevelopmental dysfunctions associated with the disease (Chamtouri et al., 2023b).

Fecal microbiota transplantation (FMT) is a safe and effective method for intestinal microecological reconstruction (Ianiro et al., 2018). As a potential therapy for gastrointestinal (GI) problems in ASD children, it has attracted increasing attention. FMT is the most effective treatment for recurrent Clostridium difficile infection (Bagdasarian et al., 2015). Microbiota transfer therapy aims to partially improve autistic behaviors by reducing the absorption of neurotoxic compounds from environmental sources or specific intestinal bacterial strains (Dolen, 2015; Pascucci et al., 2020). Animal studies have shown that transplanting fecal microbiota from patients with neurological diseases can cause GF mice to exhibit typical disease symptoms (Davies et al., 2021). Kang, D W et al. confirmed in clinical studies that ASD patients receiving FMT treatment showed significant improvements in gastrointestinal symptoms, autism-related symptoms, and gut microbiota, with long-term benefits; symptoms remained improved 2 years after treatment (Kang et al., 2019). Further clinical studies found that FMT can sustainably reduce the excessively high p-cresol levels in the intestines of autistic children and improve intestinal symptoms, emotional and behavioral abnormalities in ASD patients (Li et al., 2021).

The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines prebiotics as "substances selectively utilized by host microorganisms to confer a health benefit" (Swanson et al., 2020). Both prebiotics and probiotics can help restore the gut microbiota to normal levels and exert effects through the gut-brain axis, influencing neurotransmission and psychological status (Wang et al., 2020). Prebiotics commonly used in clinical treatment of ASD mainly include carrot powder, vitamin A, partially hydrolyzed guar gum, and galactooligosaccharides. Grimaldi, R et al. showed in a 6-week experiment that supplementation with galactooligosaccharide (GOS) prebiotics can reduce antisocial behaviors in autistic children and improve their scores on social skills scales (Grimaldi et al., 2018). Inoue, R also confirmed the therapeutic effect of prebiotics on ASD patients in his research; consumption of partially hydrolyzed guar gum prebiotics can reduce irritable behaviors in autistic children (Inoue et al., 2019).

Specifically, clinical and preclinical studies have demonstrated that certain probiotic strains, such as Lactobacillus and Bifidobacterium blends, can improve gastrointestinal symptoms and social responsiveness in ASD subjects, potentially through mechanisms involving microbial metabolite regulation and gut barrier integrity (Alli et al., 2022), and consumption of probiotics can improve gut microbiota and benefit health. Studies have shown that probiotics can produce and/or regulate tissue neurotransmitter levels, acting through the gut-brain axis (Dinan et al., 2013), so probiotics are regarded as alternative and complementary supplements for ASD treatment (Cekici and Sanlier, 2019). Relevant studies have confirmed that oral probiotics can reduce baseline or induced anxiety-like behaviors (Bravo et al., 2011; Messaoudi et al., 2011), weaken induced compulsive-like behaviors (Kantak et al., 2014), improve inflammation-related disease behaviors, and even normalize the developmental trajectory of emotion-related behaviors after early-life stress (D'Mello et al., 2015). Ying Wang et al. found in clinical studies that the levels of Bifidobacterium and Bifidobacterium longum in ASD patients were lower than those in the control group. After intervention with probiotics + fructooligosaccharides, the levels of Bifidobacterium and Bifidobacterium longum increased, gastrointestinal symptoms and ASD-related symptoms were alleviated, and the status of excessive serotonin and DA metabolic disorders in ASD patients was also reduced (Wang et al., 2020). Sanaa Y. Shaaban et al. confirmed in their research that probiotics can improve both behavioral and gastrointestinal symptoms of autism spectrum disorder (Shaaban et al., 2018). El-Ansary, A et al. confirmed in their research that probiotics stimulate inhibitory neurotransmission and can reverse impaired social interaction related to ASD (El-Ansary et al., 2018).

Although it has been well established that intervention strategies targeting the gut microbiota—such as exercise therapy, dietary intervention, FMT, prebiotics, and probiotics—are effective in the management of ASD, these approaches are associated with several limitations. Exercise therapy is advantageous due to its safety profile, minimal side effects, and ease of implementation. However, its underlying mechanisms remain poorly understood, and treatment outcomes are highly dependent on patient adherence. Furthermore, individual responses vary significantly, and therapeutic effects are often inconsistent, making it more suitable for integration into routine rehabilitation programs as an adjunctive measure in clinical practice. Dietary interventions are generally safe, practical, and can be administered at home. Nevertheless, they require strict adherence, may lead to nutritional imbalances, and lack sufficient long-term efficacy data. The development of personalized dietary plans guided by microbiota profiling may enhance their therapeutic potential. FMT demonstrates notable clinical efficacy, offers sustained benefits, and enables fundamental modulation of the gut microbiota. However, challenges include donor standardization, risk of infection, and insufficient long-term safety evidence. The integration of metagenomic analysis for precise donor-recipient matching could significantly improve its clinical applicability. Both prebiotics and probiotics exhibit favorable safety profiles, tolerability, and suitability for prolonged use. Yet, the efficacy of probiotics is strain-specific and influenced by dosage, duration of treatment, and individual tolerance, with some patients experiencing adverse reactions. Prebiotics, on the other hand, act gradually, and their effectiveness is contingent upon baseline microbial composition and exhibits considerable inter-individual variability. In clinical settings, combining personalized probiotic formulations tailored to individual microbiota profiles with prebiotic supplementation may yield superior therapeutic outcomes.